Multiple Myeloma Precursor Disease

被引:38
作者
Landgren, Ola [1 ]
Waxman, Adam Justin [1 ]
机构
[1] NCI, NIH, Ctr Canc Res, Med Oncol Branch, Bethesda, MD 20892 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2010年 / 304卷 / 21期
基金
美国国家卫生研究院;
关键词
UNDETERMINED SIGNIFICANCE MGUS; INDEPENDENT RISK-FACTOR; LIGHT-CHAIN RATIO; MONOCLONAL GAMMOPATHY; WHOLE-BODY; IMAGING TECHNIQUES; WORKING GROUP; PROGRESSION; DIAGNOSIS; PREVALENCE;
D O I
10.1001/jama.2010.1713
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent data indicate that multiple myeloma is consistently preceded by the precursor states of monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma. Currently, multiple myeloma is a clinical diagnosis based on manifestations including hypercalcemia, renal failure, anemia, and bone lesions, whereas MGUS and smoldering myeloma are diagnosed based on laboratory abnormalities. Current clinical markers allow for more individualized risk stratification and counseling of these patients. However, there is a dearth of biomarkers and molecular imaging techniques capable of (1) accurately identifying patients with disease biology corresponding with high risk of progression; (2) elucidating the mechanism of transformation to multiple myeloma; and (3) forming a framework for development of targeted therapies. This case presentation and review discusses the current understanding of myeloma precursor disease and future opportunities for improving personalized management of patients with MGUS or smoldering myeloma, as well as the potential for developing early treatment strategies designed to delay and prevent development of multiple myeloma. JAMA. 2010;304(21):2397-2404 www.jama.com
引用
收藏
页码:2397 / 2404
页数:8
相关论文
共 48 条
[1]   Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma [J].
Annunziata, Christina M. ;
Davis, R. Eric ;
Demchenko, Yulia ;
Bellamy, William ;
Gabrea, Ana ;
Zhan, Fenghuang ;
Lenz, Georg ;
Hanamura, Ichiro ;
Wright, George ;
Xiao, Wenming ;
Dave, Sandeep ;
Hurt, Elaine M. ;
Tan, Bruce ;
Zhao, Hong ;
Stephens, Owen ;
Santra, Madhumita ;
Williams, David R. ;
Dang, Lenny ;
Barlogie, Bart ;
Shaughnessy, John D., Jr. ;
Kuehl, W. Michael ;
Staudt, Louis M. .
CANCER CELL, 2007, 12 (02) :115-130
[2]   Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Importance of Whole-Body versus Spinal MR Imaging [J].
Baeuerle, Tobias ;
Hillengass, Jens ;
Fechtner, Kerstin ;
Zechmann, Christian M. ;
Grenacher, Lars ;
Moehler, Thomas M. ;
Heiss, Christiane ;
Wagner-Gund, Barbara ;
Neben, Kai ;
Kauczor, Hans-Ulrich ;
Goldschmidt, Hartmut ;
Delorme, Stefan .
RADIOLOGY, 2009, 252 (02) :477-485
[3]  
Balakumaran A, 2010, EXPERT REV MOL DIAGN, V10, P465, DOI [10.1586/erm.10.31, 10.1586/ERM.10.31]
[4]   Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease [J].
Barlogie, Bart ;
van Rhee, Frits ;
Shaughnessy, John D., Jr. ;
Epstein, Joshua ;
Yaccoby, Shmuel ;
Pineda-Roman, Mauricio ;
Hollmig, Klaus ;
Alsayed, Yazan ;
Hoering, Antje ;
Szymonifka, Jackie ;
Anaissie, Elias ;
Petty, Nathan ;
Kumar, Naveen S. ;
Srivastava, Geetika ;
Jenkins, Bonnie ;
Crowley, John ;
Zeldis, Jerome B. .
BLOOD, 2008, 112 (08) :3122-3125
[5]   F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma [J].
Bartel, Twyla B. ;
Haessler, Jeff ;
Brown, Tracy L. Y. ;
Shaughnessy, John D., Jr. ;
van Rhee, Frits ;
Anaissie, Elias ;
Alpe, Terri ;
Angtuaco, Edgardo ;
Walker, Ronald ;
Epstein, Joshua ;
Crowley, John ;
Barlogie, Bart .
BLOOD, 2009, 114 (10) :2068-2076
[6]   Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: A prospective study of 87 bone biopsies [J].
Bataille, R ;
Chappard, D ;
Basle, MF .
BLOOD, 1996, 87 (11) :4762-4769
[7]   Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma [J].
Bergsagel, PL ;
Kuehl, WM ;
Zhan, FH ;
Sawyer, J ;
Barlogie, B ;
Shaughnessy, J .
BLOOD, 2005, 106 (01) :296-303
[8]   THROMBOEMBOLIC COMPLICATIONS IN MYELOMATOSIS [J].
CATOVSKY, D ;
IKOKU, NB ;
PITNEY, WR ;
GALTON, DAG .
BRITISH MEDICAL JOURNAL, 1970, 3 (5720) :438-&
[9]   Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma [J].
Chiecchio, L. ;
Protheroe, R. K. M. ;
Ibrahim, A. H. ;
Cheung, K. L. ;
Rudduck, C. ;
Dagrada, G. P. ;
Cabanas, E. D. ;
Parker, T. ;
Nightingale, M. ;
Wechalekar, A. ;
Orchard, K. H. ;
Harrison, C. J. ;
Cross, N. C. P. ;
Morgan, G. J. ;
Ross, F. M. .
LEUKEMIA, 2006, 20 (09) :1610-1617
[10]   Genetic events in the pathogenesis of multiple myeloma [J].
Chng, W. J. ;
Glebov, O. ;
Bergsagel, R. L. ;
Kuehl, W. M. .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (04) :571-596